Press Releases

Date Title
5/23/19 Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular Dystrophy
5/8/19 Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments
5/8/19 Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
5/1/19 Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
4/30/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/8/19 Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
3/29/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28/19 Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study
3/25/19 Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
3/5/19 Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock
Displaying 41 - 50 of 620